VYNE Therapeutics (VYNE) Short Interest Ratio & Short Volume $1.64 -0.01 (-0.30%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE Therapeutics Short Interest DataVYNE Therapeutics (VYNE) has a short interest of 150,500 shares, representing 1.19% of the float (the number of shares available for trading by the public). This marks a 21.57% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.3, indicating that it would take 1.3 days of the average trading volume of 84,521 shares to cover all short positions.Current Short Interest150,500 sharesPrevious Short Interest123,800 sharesChange Vs. Previous Month+21.57%Dollar Volume Sold Short$278,425.00Short Interest Ratio1.3 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares15,210,000 sharesFloat Size12,620,000 sharesShort Percent of Float1.19%Today's Trading Volume5,980 sharesAverage Trading Volume84,521 sharesToday's Volume Vs. Average7% Short Selling VYNE Therapeutics? Sign up to receive the latest short interest report for VYNE Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVYNE Short Interest Over TimeVYNE Days to Cover Over TimeVYNE Percentage of Float Shorted Over Time Remove Ads VYNE Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2025150,500 shares $278,425.00 +21.6%1.2%1.3 $1.85 2/28/2025123,800 shares $311,976.00 -11.4%1.0%1.2 $2.52 2/15/2025139,800 shares $345,306.00 +13.5%1.1%1.4 $2.47 1/31/2025123,200 shares $289,520.00 +9.7%1.0%1.1 $2.35 1/15/2025112,300 shares $309,948.00 +82.9%0.9%1 $2.76 12/31/202461,400 shares $205,690.00 -1.6%0.5%0.5 $3.35 12/15/202462,400 shares $159,744.00 -3.0%0.5%0.7 $2.56 11/30/202464,300 shares $190,328.00 -37.1%0.5%0.8 $2.96 11/15/2024102,200 shares $275,940.00 +23.7%0.8%1.3 $2.70 10/31/202482,600 shares $224,672.00 +65.2%0.7%1.2 $2.72 Get the Latest News and Ratings for VYNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/202450,000 shares $100,000.00 -14.1%0.4%1 $2.00 9/30/202458,200 shares $109,416.00 +75.8%0.5%1.3 $1.88 9/15/202433,100 shares $60,904.00 -28.8%0.3%0.7 $1.84 8/31/202446,500 shares $84,630.00 -20.0%0.4%0.9 $1.82 8/15/202458,100 shares $108,066.00 -13.0%0.5%1.1 $1.86 7/31/202466,800 shares $126,920.00 +8.1%0.5%1.3 $1.90 7/15/202461,800 shares $139,050.00 +10.6%0.5%1.1 $2.25 6/30/202455,900 shares $110,123.00 -10.9%0.5%1 $1.97 6/15/202462,700 shares $144,210.00 +22.2%0.5%0.7 $2.30 5/31/202451,300 shares $130,302.00 -10.6%0.4%0.6 $2.54 5/15/202457,400 shares $160,720.00 -30.0%0.5%0.6 $2.80 4/30/202482,000 shares $206,640.00 -15.3%0.7%0.8 $2.52 4/15/202496,800 shares $248,776.00 +13.1%0.8%0.9 $2.57 3/31/202485,600 shares $262,792.00 +590.3%0.7%0.7 $3.07 3/15/202412,400 shares $24,924.00 -63.4%0.1%0.1 $2.01 2/29/202433,900 shares $75,597.00 -5.3%0.3%0.3 $2.23 2/15/202435,800 shares $77,328.00 -31.8%0.3%0.4 $2.16 1/31/202452,500 shares $89,775.00 -40.3%0.4%0.5 $1.71 1/15/202488,000 shares $181,280.00 No Change0.7%0.2 $2.06 12/31/202388,000 shares $205,040.00 +1,157.1%N/A0.2 $2.33 12/15/20237,000 shares $19,180.00 -94.4%0.1%0 $2.74 11/30/2023124,800 shares $413,088.00 -15.0%1.0%0.4 $3.31 11/15/2023146,800 shares $604,816.00 +150.9%1.2%0.4 $4.12 10/31/202358,500 shares $178,425.00 +11.6%1.9%0.2 $3.05 10/15/202352,400 shares $144,100.00 -7.6%1.7%3.3 $2.75 9/30/202356,700 shares $229,068.00 -8.1%1.8%3.5 $4.04 9/15/202361,700 shares $237,545.00 -0.2%2.0%4.1 $3.85 8/31/202361,800 shares $268,830.00 -19.7%2.0%3.7 $4.35 8/15/202377,000 shares $373,450.00 +13.1%2.4%3.7 $4.85 7/31/202368,100 shares $316,665.00 +3.8%2.2%2 $4.65Trump’s betrayal exposed (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 7/15/202365,600 shares $276,832.00 -6.0%2.1%0.7 $4.22 6/30/202369,800 shares $286,180.00 -5.6%2.2%0.1 $4.10 6/15/202373,900 shares $352,281.30 +13.7%2.4%0.1 $4.77 5/31/202365,000 shares $408,850.00 -29.3%2.1%0.1 $6.29 5/15/202391,900 shares $705,792.00 -55.6%2.9%0.1 $7.68 4/30/2023206,800 shares $1.09 million +119.1%6.6%0.3 $5.26 4/15/202394,400 shares $256,768.00 -3.9%3.0%0.1 $2.72 3/31/202398,200 shares $302,456.00 +30.2%3.1%1.7 $3.08 3/15/202375,400 shares $192,270.00 +38.1%2.3%1 $2.55 2/28/202354,600 shares $182,091.00 -2.5%1.7%0.8 $3.34 2/15/202356,000 shares $196,560.00 -94.6%1.8%0.8 $3.51 1/31/20231,030,000 shares $267,800.00 -29.0%N/A0.8 $0.26 1/15/20231,450,000 shares $388,311.45 +105.2%N/A1.2 $0.27 12/30/2022706,800 shares $106,020.00 -7.4%N/A0.6 $0.15 12/15/2022763,400 shares $129,472.64 -4.3%N/A3.5 $0.17 11/30/2022797,700 shares $185,545.02 +3.5%N/A4.3 $0.23 11/15/2022770,600 shares $189,297.89 -3.6%N/A4.3 $0.25 10/31/2022799,300 shares $204,301.08 +3.2%N/A2.7 $0.26 10/15/2022774,400 shares $187,792.00 +0.0%N/A2.6 $0.24 9/30/2022774,200 shares $172,724.02 -22.4%N/A2.6 $0.22 9/15/2022997,900 shares $282,405.70 +48.9%N/A3.1 $0.28 8/31/2022670,200 shares $209,973.66 -6.0%N/A1.9 $0.31 8/15/2022713,200 shares $228,224.00 -4.9%N/A1.9 $0.32 7/31/2022750,300 shares $324,204.63 -15.5%N/A2.5 $0.43 7/15/2022887,400 shares $399,330.00 -22.8%N/A2.6 $0.45 6/30/20221,150,000 shares $447,350.00 -9.5%N/A2 $0.39 6/15/20221,270,000 shares $660,400.00 +5.0%N/A2 $0.52 5/31/20221,210,000 shares $492,954.00 -11.7%N/A1.8 $0.41 5/15/20221,370,000 shares $545,260.00 -12.7%N/A2 $0.40 4/30/20221,570,000 shares $659,400.00 +8.3%N/A2.1 $0.42 4/15/20221,450,000 shares $767,050.00 +57.0%N/A1.7 $0.53 3/31/2022923,800 shares $600,562.38 -19.0%N/A0.8 $0.65 3/15/20221,140,000 shares $638,400.00 -22.5%N/A1 $0.56 2/28/20221,470,000 shares $796,740.00 -6.4%N/A0.5 $0.54 2/15/20221,570,000 shares $893,487.00 -23.4%N/A0.6 $0.57 1/31/20222,050,000 shares $1.27 million +12.6%N/A0.7 $0.62 1/15/20221,820,000 shares $1.25 million -12.5%N/A0.7 $0.69 12/31/20212,080,000 shares $2.12 million -34.0%N/A0.9 $1.02 12/15/20213,150,000 shares $3.59 million +283.4%N/A1.3 $1.14 11/30/2021821,600 shares $846,248.00 -11.7%N/A0.6 $1.03 11/15/2021930,900 shares $1.19 million +5.5%N/A1.3 $1.28 10/29/2021882,000 shares $1.18 million +1.5%1.7%1 $1.34 10/15/2021869,400 shares $1.06 million -9.6%1.7%1 $1.22 9/30/2021962,100 shares $1.34 million -23.0%1.9%1.3 $1.39 9/15/20211,250,000 shares $1.85 million -11.4%2.5%1.5 $1.48 8/31/20211,410,000 shares $2.40 million -50.4%2.8%1.6 $1.70 8/13/20212,840,000 shares $5.06 million -6.6%5.6%3.2 $1.78 7/30/20213,040,000 shares $8.21 million +7.8%6.0%4.1 $2.70 7/15/20212,820,000 shares $7.76 million +9.7%5.6%3.2 $2.75 6/30/20212,570,000 shares $9.02 million -35.6%5.1%2.8 $3.51Trump’s Secret Weapon (Ad)Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.Get Your FREE Presidential Transition Guide Today 6/15/20213,990,000 shares $14.52 million -1.2%7.9%4.6 $3.64 5/28/20214,040,000 shares $15.96 million -7.3%8.0%4.6 $3.95 5/14/20214,360,000 shares $14.13 million +15.7%8.6%4.4 $3.24 4/30/20213,770,000 shares $19.34 million +13.2%7.5%2.5 $5.13 4/15/20213,330,000 shares $18.78 million -0.9%6.6%1.4 $5.64 3/31/20213,360,000 shares $22.14 million +14.7%6.7%1.4 $6.59 3/15/20212,930,000 shares $21.65 million +7.7%5.8%1.3 $7.39 2/26/20212,720,000 shares $21.46 million -71.8%5.4%1.2 $7.89 2/12/20219,660,000 shares $102.78 million -7.9%19.7%4.8 $10.64 1/29/202110,490,000 shares $93.57 million +15.2%5.8%1.6 $8.92 1/15/20219,110,000 shares $60.13 million No Change5.7%2.4 $6.60 8/14/20209,960,000 shares $64.14 million -3.7%N/A2.2 $6.44 7/31/202010,340,000 shares $66.59 million +19.0%N/A2.1 $6.44 7/15/20208,690,000 shares $56.31 million -22.7%N/A1.7 $6.48 6/30/202011,240,000 shares $81.38 million +62.0%N/A2.1 $7.24 6/15/20206,940,000 shares $61.07 million +44.9%N/A1.4 $8.80 5/29/20204,790,000 shares $45.79 million +20.1%N/A1.2 $9.56 5/15/20203,990,000 shares $26.97 million -29.6%N/A1.4 $6.76 4/30/20205,670,000 shares $41.28 million +9.7%N/A2.8 $7.28 4/15/20205,170,000 shares $28.75 million +106.0%N/A3.7 $5.56 VYNE Short Interest - Frequently Asked Questions What is VYNE Therapeutics' current short interest? Short interest is the volume of VYNE Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 150,500 shares of VYNE short. 1.19% of VYNE Therapeutics' shares are currently sold short. Learn More on VYNE Therapeutics' current short interest. What is a good short interest ratio for VYNE Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VYNE shares currently have a short interest ratio of 1.0. Learn More on VYNE Therapeutics's short interest ratio. Which institutional investors are shorting VYNE Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of VYNE Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for VYNE Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.19% of VYNE Therapeutics' floating shares are currently sold short. Is VYNE Therapeutics' short interest increasing or decreasing? VYNE Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 150,500 shares, an increase of 21.6% from the previous total of 123,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is VYNE Therapeutics' float size? VYNE Therapeutics currently has issued a total of 15,210,000 shares. Some of VYNE Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. VYNE Therapeutics currently has a public float of 12,620,000 shares. How does VYNE Therapeutics' short interest compare to its competitors? 1.19% of VYNE Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to VYNE Therapeutics: Nkarta, Inc. (14.59%), XBiotech Inc. (4.10%), Immunic, Inc. (2.66%), Silence Therapeutics plc (4.71%), Galectin Therapeutics Inc. (18.94%), Anixa Biosciences, Inc. (1.29%), Kyverna Therapeutics, Inc. (14.62%), Biomea Fusion, Inc. (32.82%), Black Diamond Therapeutics, Inc. (13.89%), Jaguar Health, Inc. (0.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short VYNE Therapeutics stock? Short selling VYNE is an investing strategy that aims to generate trading profit from VYNE Therapeutics as its price is falling. VYNE shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against VYNE Therapeutics? A short squeeze for VYNE Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VYNE, which in turn drives the price of the stock up even further. How often is VYNE Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VYNE, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies Nkarta Short Interest Data XBiotech Short Interest Data Immunic Short Interest Data Silence Therapeutics Short Interest Data Galectin Therapeutics Short Interest Data Anixa Biosciences Short Interest Data Kyverna Therapeutics Short Interest Data Biomea Fusion Short Interest Data Black Diamond Therapeutics Short Interest Data Jaguar Health Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VYNE) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
